Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEPHYRUS-1: Pamrevlumab in Idiopathic Pulmonary Fibrosis
NCT03955146Phase 3Terminated
- Sponsor
- FibroGen
- Start
- Jun 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) (6 arms), sponsored by FibroGen. Primary endpoint: Change From Baseline in Forced Vital Capacity at 48 weeks. Started Jun 2019; status: terminated.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03955146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955146.